Evidence map›Paper›PMID 40982357›Full record

ArticleEpilepsia open2025

Nonseizure symptoms and broader seizure impacts in patients with Dravet syndrome and Lennox-Gastaut syndrome in clinical practice settings: Results from a multinational survey.

Drishti Shah, Vicente Villanueva, Dennis Dlugos, Arturo Benitez, Yasmin Taylor, Stevie Olsen, Hannah Connolly, Sophie Lai, J Scott Andrews

Abstract read
In one paragraph

Article in Epilepsia open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Drishti ShahTakeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.ORCID https://orcid.org/0000-0002-5866-7743
Vicente VillanuevaHospital Universitario y Politécnico La Fe, Valencia, Spain.ORCID https://orcid.org/0000-0003-2080-8042
Dennis DlugosThe Children's Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0003-3088-7645
Arturo BenitezTakeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.ORCID https://orcid.org/0000-0001-6023-9871
Yasmin TaylorAdelphi Real World, Bollington, UK.ORCID https://orcid.org/0000-0003-4454-5013
Stevie OlsenAdelphi Real World, Bollington, UK.ORCID https://orcid.org/0000-0002-8911-0155
Hannah ConnollyAdelphi Real World, Bollington, UK.ORCID https://orcid.org/0000-0003-4479-1126
Sophie LaiAdelphi Real World, Bollington, UK.ORCID https://orcid.org/0000-0003-3149-5504
J Scott AndrewsTakeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.ORCID https://orcid.org/0009-0001-5516-7719

Funding

Takeda Development Center Americas, Inc.
6 · The paper itself

Abstract

objectiveTo assess the burden of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), including managing seizure and nonseizure symptoms, on patients and caregivers.

methodsData were drawn from the Adelphi Real World DS and LGS Disease Specific Programme™, a cross-sectional survey in Asia (China, Japan), Europe (France, Germany, Italy, Spain, United Kingdom), and the United States of America between July 2022 and August 2023. Neurologists/pediatric neurologists reported demographics, clinical characteristics, and nonseizure symptoms for up to 10 consecutively consulting patients. Caregivers provided data on patient nonseizure symptoms, quality of life (QoL), satisfaction with treatment, and caregiver burden. Analyses were descriptive.

resultsPhysicians (n = 259) reported data on 547 patients with DS and 811 with LGS. Caregivers (n = 348) provided data on 157 patients with DS and 191 with LGS. In the previous 6 months, 51% of patients with DS experienced ≥1 seizure-related injury and 61% experienced status epilepticus. For LGS, this was 50% and 43% of patients, respectively. Rates of moderate to very severe impairment in nonseizure symptoms were reported by physicians in learning/intellect (DS 69%; LGS 78%), verbal communication (DS 69%; LGS 71%), severity of developmental delay (DS 65%; LGS 68%), overall mental status (DS 57%; LGS 67%), and nonverbal communication (DS 61%; LGS 64%). Caregivers reported moderate to very severe impairment in learning/intellect (DS 53%; LGS 67%), severity of developmental delay (DS 52%; LGS 56%), verbal communication (DS 48%; LGS 48%), and nonverbal communication (DS 42%; LGS 45%). Caregivers reported nonseizure symptoms moderately to significantly impacted QoL for 56% of patients (DS 49%; LGS 61%); satisfaction with treatment rate was low for control over cognition/memory, verbal communication, and nonverbal communication impairment. SIGNIFICANCE: In this study, considerable burden in DS and LGS management and care was driven by nonseizure symptoms, suggesting a need for treatments that manage the broad spectrum of disease symptoms. PLAIN LANGUAGE SUMMARY: We asked doctors and caregivers to tell us about the symptoms that patients with Dravet syndrome and Lennox-Gastaut syndrome have. We asked how the symptoms affect the lives of the patients as well as the caregivers. We found that seizures have a big impact on the health and well-being of patients and caregivers. We also found that other symptoms not caused by seizures have a big impact on patients and their caregivers.

Indexed as

Epilepsies, MyoclonicLennox Gastaut SyndromeSeizuresAdolescentAdultCaregiversChildChild, PreschoolCost of IllnessCross-Sectional StudiesFemaleHumansMaleMiddle AgedQuality of LifeSurveys and Questionnairescaregiverdisease burdenDravet syndromeLennox–Gastaut syndromenonseizure symptoms

Identifiers

PMID40982357
PMCPMC12716298

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.